Sorry, you need to enable JavaScript to visit this website.

Competitive Grants Program

Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.

Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.

Sign Up for Alerts Details
  • Title
    Grant Type
    Focus Area
    Country
    Application Due Date
    Optimizing Antimicrobial Stewardship (AMS) Interventions and Outcomes in Clinical Outcomes, Optimal Use and Resource Utilizatio
    Release Date:
    Review Process: Pfizer Internal
    Research Inflammation & Immunology China
    Optimizing Disease Management to Improve Alopecia Areata Quality of Care
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Inflammation & Immunology China
    Research on Exploring Disease Assessment and Prioritizing Systematic Treatment for Vitiligo
    Release Date:
    Review Process: Pfizer Internal
    Research Inflammation & Immunology China
    Quality Improvement in Molecular Testing Pathways for Metastatic Colorectal Cancer (mCRC)
    Release Date:
    Partner: American Society for Clinical Pathology (ASCP)
    Review Process: Expert Review Panel
    Quality Improvement Oncology USA
    Personalized monitoring&treatment for HR+, HER2- mBC patients treated w CDK4/6i: incorporating Patient complexity risk factors
    Release Date:
    Review Process: Expert Review Panel
    Quality Improvement, Research Oncology Italy
    Providing Appropriate Medical Care for IBD Patients
    Release Date:
    Partner: Japanese Society for Inflammatory Bowel Disease (JSIBD)
    Review Process: Expert Review Panel
    Translation: Japanese (link)
    Quality Improvement Inflammation & Immunology Japan
    Administration of brentuximab vedotin alone or in combination with other approved agents in pre and/or peri CAR-T
    Release Date:
    Review Process: Pfizer Internal
    Research Oncology USA
    Fostering Educational Initiatives for ALK+ Metastatic Non-Small Cell Lung Cancer(mNSCLC) Tyrosine Kinase Inhibitors(TKI) Therapy
    Release Date:
    Review Process: Pfizer Internal
    Translation: French (link)
    Education Oncology Canada
    2026 Inflammatory Bowel Disease (IBD) Fellowship- United States
    Release Date:
    Review Process: Expert Review Panel
    Fellowship Inflammation & Immunology USA
  • Title
    Grant Type
    Focus Area
    Country
    Application Due Date
    Research on Disease Burden of CRE (including non-MBL and MBL-CRE), CR-PA and Stenotrophomonas Maltophilia in China
    Release Date:
    Review Process: Pfizer Internal
    Research Hospital China
    Research on Diagnostic and Treatment of Invasive Mold Disease
    Release Date:
    Review Process: Pfizer Internal
    Research Hospital China
    Optimizing Care for Patients with HR+/HER2- or HER2+ (regardless of hormonal status) metastatic Breast Cancer (mBC)
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology Spain
    Educational approaches to address immunization practice gaps and improve adult vaccination coverage in Switzerland
    Release Date:
    Review Process: Pfizer Internal
    Education Vaccines Switzerland
    Improving Patient Care of Lower Respiratory Tract Infection Among Infants
    Release Date:
    Review Process: Expert Review Panel
    Quality Improvement Vaccines Thailand
    China Medical Education in Non-small Cell Lung Cancer Diagnosis, Treatment and Long-Term Disease Management
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology China
    Diagnosis and Treatment of Cancer Cachexia
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology France, Germany, Italy, Japan, Spain, USA, United Kingdom
    Healthcare Optimization and Patient Equity for Lung Cancer in China (“HOPE”)
    Release Date:
    Partner: The International Association for the Study of Lung Cancer (IASLC)
    Review Process: Expert Review Panel
    Quality Improvement Oncology China
    Optimizing ER+ Metastatic Breast Cancer Treatment: incorporating emerging treatment options and biomarker testing
    Release Date:
    Partner: Arvinas
    Review Process: Pfizer Internal
    Education Oncology All
    Optimizing vaccination pathways among at-risk or immunocompromised adults and the elderly in Italy​
    Release Date:
    Review Process: Expert Review Panel
    Quality Improvement Vaccines Italy
    Expanding Access to Maternal Immunization Resources and Point-of-Care Tools
    Release Date:
    Review Process: Pfizer Internal
    Education Vaccines USA
    Optimizing ATTR-CM Diagnosis and Care in Heart Failure Patients Quality Improvement Grant Program Request for Proposals
    Release Date:
    Partner: American College of Cardiology
    Review Process: Expert Review Panel
    Quality Improvement Rare Disease USA